​Prof. Declan Doogan, Chairman. 
Declan has over 30 years of industry experience in both major pharma and biotech. He was the Head of Worldwide Development at Pfizer, where many multi-billion-dollar programs were delivered (e.g., Viagra, Lipitor and Zoloft). He has held a number of executive positions in Pfizer in the US, the UK and Japan. Since leaving Pfizer in 2007 he has been engaged in executive roles in small pharma. 
Declan was CMO and acting CEO of Amarin (AMRN: Nasdaq), transforming it from a failing neuroscience company to a vibrant cardiovascular company. He went on to co-found Biohaven (BHVN: NYSE) specialising in neurology and psychiatry. Declan is also an investor in emerging biotechnology and technology companies. He holds a number of board appointments, principally in pharma companies, and has also Visiting Professor at Glasgow University Medical School.